[go: up one dir, main page]

HUP0100427A2 - ACE inhibítor - MMP inhibitor-kombinációk - Google Patents

ACE inhibítor - MMP inhibitor-kombinációk

Info

Publication number
HUP0100427A2
HUP0100427A2 HU0100427A HUP0100427A HUP0100427A2 HU P0100427 A2 HUP0100427 A2 HU P0100427A2 HU 0100427 A HU0100427 A HU 0100427A HU P0100427 A HUP0100427 A HU P0100427A HU P0100427 A2 HUP0100427 A2 HU P0100427A2
Authority
HU
Hungary
Prior art keywords
inhibitor
combinations
mmp
ace
effective amount
Prior art date
Application number
HU0100427A
Other languages
English (en)
Inventor
Joseph Thomas Peterson
Milton Lethan Pressler
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0100427(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of HUP0100427A2 publication Critical patent/HUP0100427A2/hu
Publication of HUP0100427A3 publication Critical patent/HUP0100427A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgya gyógyszerkészítmény, amely egy angiotenzinátalakító enzim inhibitor hatásos mennyiségét és egy mátrixmetalloproteináz inhibitor hatásos mennyiségét tartalmazza. Atalálmány szerinti gyógyszerkészítmény fibrózis, ventrikuláristágulat, és/vagy szívgyengeség kezelésére használható. Ó
HU0100427A 1997-12-23 1998-11-10 Ace inhibitor-mmp inhibitor combinations HUP0100427A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6859497P 1997-12-23 1997-12-23
PCT/US1998/023993 WO1999032150A1 (en) 1997-12-23 1998-11-10 Ace inhibitor-mmp inhibitor combinations

Publications (2)

Publication Number Publication Date
HUP0100427A2 true HUP0100427A2 (hu) 2001-06-28
HUP0100427A3 HUP0100427A3 (en) 2002-11-28

Family

ID=22083543

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100427A HUP0100427A3 (en) 1997-12-23 1998-11-10 Ace inhibitor-mmp inhibitor combinations

Country Status (24)

Country Link
US (1) US6133304A (hu)
EP (1) EP1047450B1 (hu)
JP (1) JP2001526245A (hu)
KR (1) KR20010033473A (hu)
AR (1) AR015504A1 (hu)
AT (1) ATE225187T1 (hu)
AU (1) AU751701B2 (hu)
BR (1) BR9814422A (hu)
CA (1) CA2305436A1 (hu)
CO (1) CO4970775A1 (hu)
DE (1) DE69808518T2 (hu)
DK (1) DK1047450T3 (hu)
ES (1) ES2184340T3 (hu)
HU (1) HUP0100427A3 (hu)
IL (1) IL135428A0 (hu)
IS (1) IS5446A (hu)
NO (1) NO20003256D0 (hu)
NZ (1) NZ503962A (hu)
PE (1) PE20000065A1 (hu)
PL (1) PL341335A1 (hu)
PT (1) PT1047450E (hu)
UY (1) UY25321A1 (hu)
WO (1) WO1999032150A1 (hu)
ZA (1) ZA9811794B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366954A1 (en) * 1999-03-03 2000-09-08 The Procter & Gamble Company Dihetero-substituted metalloprotease inhibitors
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
AU2002243692B2 (en) 2001-01-29 2006-06-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
EP1419767A4 (en) * 2001-08-20 2005-03-16 Ono Pharmaceutical Co MEDICINE FOR TREATMENT OF HEART FAILURE
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
WO2004032708A2 (en) * 2002-10-04 2004-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vasoregulating compounds and methods of their use
EP1575511A4 (en) * 2002-11-07 2006-06-28 Us Gov Health & Human Serv NEW TARGET FOR ANGIOGENESIS AND ANTI-ANGIOGENESIS THERAPY
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
AU2004263900A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
EP1684719B1 (en) * 2003-11-14 2011-10-26 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
EP1737499A4 (en) 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
MX2007001337A (es) * 2004-08-02 2008-03-13 Genmedica Therapeutics Sl Compuestos para inhibir amina-oxidasas que contienen cobre y usos de los mismos.
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
CA2728766A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2013506684A (ja) * 2009-10-01 2013-02-28 シンフォニー エボリューション， インコーポレイテッド マトリックスメタロプロテアーゼ−２阻害剤を用いた、動脈瘤性拡張、血管壁脆弱性、特に腹部大動脈瘤および胸部動脈瘤を治療する方法
KR20140072037A (ko) 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
EA027451B1 (ru) 2011-08-30 2017-07-31 Схди Фаундейшн, Инк. Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и их применение
US9884085B2 (en) 2013-06-26 2018-02-06 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
US20190008828A1 (en) 2015-12-28 2019-01-10 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO115786B1 (ro) * 1990-05-11 2000-06-30 Pfizer Compozitie pentru scaderea presiunii sangelui sau tratarea atacurilor cardiace congestive, la mamifere, si metoda de tratament
NZ305528A (en) * 1995-02-10 2001-05-25 G Combination of angiotensin converting enzyme inhibitor and an aldosterone antagonist
EA001561B1 (ru) * 1996-05-17 2001-04-23 Варнер-Ламберт Компани Бифенилсульфонамидные ингибиторы матричных металлопротеиназ
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
CO4970775A1 (es) 2000-11-07
HUP0100427A3 (en) 2002-11-28
AU1522099A (en) 1999-07-12
DK1047450T3 (da) 2003-01-27
EP1047450B1 (en) 2002-10-02
UY25321A1 (es) 2004-07-30
DE69808518T2 (de) 2003-06-26
NZ503962A (en) 2002-03-28
BR9814422A (pt) 2000-10-10
AR015504A1 (es) 2001-05-02
PE20000065A1 (es) 2000-02-11
US6133304A (en) 2000-10-17
KR20010033473A (ko) 2001-04-25
IS5446A (is) 2000-04-14
AU751701B2 (en) 2002-08-22
ZA9811794B (en) 1999-06-29
JP2001526245A (ja) 2001-12-18
CA2305436A1 (en) 1999-07-01
ES2184340T3 (es) 2003-04-01
IL135428A0 (en) 2001-05-20
PT1047450E (pt) 2003-02-28
ATE225187T1 (de) 2002-10-15
NO20003256L (no) 2000-06-22
DE69808518D1 (de) 2002-11-07
WO1999032150A1 (en) 1999-07-01
NO20003256D0 (no) 2000-06-22
EP1047450A1 (en) 2000-11-02
PL341335A1 (en) 2001-04-09

Similar Documents

Publication Publication Date Title
HUP0100427A2 (hu) ACE inhibítor - MMP inhibitor-kombinációk
RU94028653A (ru) Фармацевтический препарат
BR9908280A (pt) Inibidores de enzimas de fosfolipase
AU5493598A (en) N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
AU3967195A (en) Amidino and guanidino substituted inhibitors of trypsin-like enzymes
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
HK1021178A1 (en) The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
IL129148A0 (en) The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
CA2136331A1 (en) New pharmaceutical uses of krill enzymes
DK0470136T3 (da) Terapeutisk middel
HUP0004544A2 (hu) Angiotenzin-átalakító enzim inhibitora és diuretikum kombinációjának alkalmazása mikrokeringési rendellenességek kezelésére szolgáló gyógyászati készítmény előállítására
AU5498296A (en) Transdermally administrable medicament with ACE inhibitors
ME00578A (en) Use of gastrointestinal lipase inhibitors
NO962581L (no) Preparater for hvitgjöring av tenner
CA2128711A1 (en) Trypsin inhibitors
NO993670D0 (no) Quinoksalin i trippelkombinasjon med proteaseinhibitorer og reverse transkriptaseinhibitorer som medikament for behandling av AIDS
NO960775D0 (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
HUP9901353A2 (hu) ACE-inhibitorok alkalmazása diszpepsziás tünetek kezelésére alkalmas gyógyszerkészítmény előállítására
NO955258D0 (no) Medisinsk anvendelse av enzymer
AU2056397A (en) Hydroxyazepanes as inhibitors of glycosidase and hiv protease
ES2186782T3 (es) Uso de derivados de tropolona como inhibidores de la enzima inositol-monofosfatasa.
DE3774947D1 (de) Alpha-acylamino-aminoalkyl-phosphonat-inhibitor des angiotensin umwandelnden enzyms.
AU5967486A (en) Support used in bioluminescent dosing of enzymes, substrates or enzymatic inhibitors
HUP9900942A2 (hu) In situ képződő gyógyszerforma enzimek sebekre való juttatására